Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BNTC

Benitec Biopharma Inc

Feb 13 • 02:26PM ET

10.85

-0.49 -4.32 %

Healthcare • Biotechnology • USA • NASD

Feb 12, 11:17 AMBenitec Biopharma posts fiscal Q4 2025 results with non-GAAP EPS of -$0.26 (+21% YoY) on $0 revenue, missing EPS but beating revenue estimates, and reports a fiscal Q2 2026 net loss of $11.8M while unveiling BB-301 Phase 1b/2a data showing all four Cohort 1 completers as 12‑month responders with durable benefits and 24‑month improvement in Patient 1.

Peers: MRNA IONS ALNY CRSP ARWR NTLA SRPT EDIT SGMO QURE

| Held by: VTI IWM VXF IWO PINK VTWO IWC VTWG GSSC RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.01	Insider Own	2.74%	Shs Outstand	34.25M	Perf Week	-10.48%
Market Cap	371.61M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	178.15%	Shs Float	33.32M	Perf Month	-10.55%
Enterprise Value	277.84M	PEG	-	EPS next Q	-0.27	Inst Own	82.79%	Short Float	6.28%	Perf Quarter	-19.27%
Income	-34.48M	P/S	-	EPS this Y	-5.87%	Inst Trans	2.13%	Short Ratio	11.37	Perf Half Y	-14.30%
Sales	0.00M	P/B	3.04	EPS next Y	9.37%	ROA	-41.85%	Short Interest	2.09M	Perf YTD	-19.45%
Book/sh	3.57	P/C	3.93	EPS next 5Y	5.01%	ROE	-43.71%	52W High	17.15 -36.73%	Perf Year	11.86%
Cash/sh	2.76	P/FCF	-	EPS past 3/5Y	69.76% 62.31%	ROIC	-36.68%	52W Low	9.70 11.86%	Perf 3Y	136.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.83% 5.36%	Perf 5Y	-87.11%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	80.95%	Oper. Margin	-	ATR (14)	0.75	Perf 10Y	-98.74%
Dividend Ex-Date	-	Quick Ratio	46.95	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	36.48	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	46.95	EPS Q/Q	54.58%	SMA20	-9.94%	Beta	0.30	Target Price	25.20
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-11.94%	Rel Volume	0.85	Prev Close	11.34
Employees	19	LT Debt/Eq	0.00	Earnings	Feb 12 BMO	SMA200	-18.75%	Avg Volume	183.92K	Price	10.85
IPO	Jun 23, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.44% -	Trades		Volume	121,142	Change	-4.32%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-25	Initiated	TD Cowen	Buy
Dec-16-24	Initiated	H.C. Wainwright	Buy	$28
Dec-13-24	Initiated	Robert W. Baird	Outperform	$30
Oct-16-24	Initiated	Oppenheimer	Outperform	$35
Sep-12-24	Initiated	Guggenheim	Buy	$17
Jul-22-24	Initiated	Leerink Partners	Outperform	$13
Jun-13-24	Initiated	Piper Sandler	Overweight	$30
Oct-05-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Apr-20-20	Initiated	Ladenburg Thalmann	Buy	$14
Feb-26-16	Downgrade	Maxim Group	Buy → Hold
Dec-31-15	Reiterated	Maxim Group	Buy	$23 → $14
Sep-16-15	Reiterated	Maxim Group	Buy	$4 → $23

Show Previous Ratings

Feb-12-26 08:30AM	Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update (GlobeNewswire)
Jan-11-26 08:00AM	Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response (GlobeNewswire)
Dec-24-25 09:55AM	Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect? (Zacks)
Dec-05-25 09:55AM	Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know (Zacks)
Dec-03-25 09:35AM	Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) (Zacks) +7.98%
06:16AM	Loading…
Nov-18-25 06:16AM	Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment (Insider Monkey)
Nov-14-25 05:00PM	Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update (GlobeNewswire)
Nov-12-25 09:45AM	Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others (24/7 Wall St.)
Nov-06-25 12:19AM	Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering (GlobeNewswire) -23.95%
Nov-05-25 04:43PM	Benitec Biopharma Inc. Announces Proposed Public Offering (GlobeNewswire)
Nov-03-25 07:10AM	Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 (GlobeNewswire)
07:00AM	Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors (GlobeNewswire)
Nov-02-25 07:00PM	Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy (GlobeNewswire)
Sep-22-25 04:05PM	Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update (GlobeNewswire)
Jul-09-25 08:00AM	Benitec Biopharma Provides Operational Updates (GlobeNewswire) +9.67%
09:40AM	Loading…
Jun-20-25 09:40AM	Is Cintas (CTAS) Stock Outpacing Its Business Services Peers This Year? (Zacks)
09:40AM	Is Ardagh Metal Packaging (AMBP) Stock Outpacing Its Industrial Products Peers This Year? (Zacks)
09:40AM	Are Basic Materials Stocks Lagging Harmony Gold (HMY) This Year? (Zacks)
09:40AM	Is Root (ROOT) Stock Outpacing Its Finance Peers This Year? (Zacks)
09:40AM	Are Utilities Stocks Lagging CenterPoint Energy (CNP) This Year? (Zacks)
09:40AM	Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:40AM	Has Karooooo (KARO) Outpaced Other Computer and Technology Stocks This Year? (Zacks)
09:40AM	Are Consumer Staples Stocks Lagging Ahold (ADRNY) This Year? (Zacks)
09:40AM	Are Auto-Tires-Trucks Stocks Lagging Aisin Seiki (ASEKY) This Year? (Zacks)
Jun-16-25 08:50AM	Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jun-05-25 09:55AM	Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? (Zacks)
Jun-04-25 09:40AM	Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year? (Zacks)
May-29-25 08:50AM	Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why (Zacks)
May-20-25 09:55AM	Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet (Zacks)
May-19-25 09:40AM	Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year? (Zacks)
07:00AM	Loading…
May-14-25 07:00AM	Benitec Biopharma Releases Third Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 08:50AM	Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-02-25 09:40AM	Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-30-25 10:17AM	Will Declining Medical Customers Affect Cigna's Q1 Earnings? (Zacks)
Apr-25-25 09:55AM	Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade (Zacks)
Apr-23-25 12:00PM	What Makes Benitec Biopharma (BNTC) a New Buy Stock (Zacks)
Apr-16-25 09:40AM	Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? (Zacks)
Apr-15-25 11:51PM	Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-25-25 08:00AM	Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering (GlobeNewswire)
Mar-19-25 07:00AM	Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Feb-26-25 07:00AM	Benitec Biopharma to Participate in Upcoming Conferences in March (GlobeNewswire)
Feb-20-25 09:55AM	Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know (Zacks)
Feb-14-25 08:10AM	Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update (GlobeNewswire) +15.98%
08:00AM	Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Jan-27-25 08:00AM	Benitec Biopharma to Participate in Upcoming Conferences in January and February (GlobeNewswire)
Jan-13-25 09:49AM	Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock (Zacks) -5.55%
Dec-17-24 06:25AM	Benitec Biopharma initiated with a Buy at H.C. Wainwright (TipRanks)
Dec-09-24 09:55AM	Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? (Zacks) +8.46%
08:50AM	Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-26-24 07:00AM	Benitec Biopharma to Participate in Upcoming Investor Conferences in December (GlobeNewswire)
Nov-14-24 04:30PM	Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update (GlobeNewswire)
Nov-04-24 08:00AM	Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference (GlobeNewswire)
Oct-25-24 05:01PM	Janus Henderson Group PLC Expands Investment in Benitec Biopharma Inc (GuruFocus.com)
Oct-14-24 06:00AM	Benitec Biopharma Announces Updated Investor Webcast Information (GlobeNewswire) -6.45%
Oct-12-24 06:30AM	Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-30-24 09:03PM	Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc (GuruFocus.com) +19.42%
Sep-26-24 04:30PM	Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update (GlobeNewswire) +5.01%
Sep-18-24 08:00AM	Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-17-24 08:00AM	Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar (GlobeNewswire)
Jul-15-24 06:00AM	Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study (GlobeNewswire) +7.71%
Jul-01-24 07:00AM	Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors (GlobeNewswire)
May-13-24 02:53PM	BNTC Stock Earnings: Benitec Biopharma Misses EPS for Q3 2024 (InvestorPlace) -12.22%
08:15AM	Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
May-01-24 08:00AM	Benitec Biopharma to Participate in the Citizens JMP Life Science Conference (GlobeNewswire) -6.51%
Apr-18-24 07:30AM	Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study (GlobeNewswire) +42.08%
07:00AM	Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million (GlobeNewswire)
Apr-09-24 08:00AM	Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024 (GlobeNewswire)
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Feb-13-24 08:00AM	Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Nov-30-23 07:00AM	Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (GlobeNewswire)
Nov-17-23 08:00AM	Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-13-23 08:00AM	Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Sep-21-23 08:00AM	Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update (GlobeNewswire)
Aug-21-23 09:02PM	Citadel Advisors LLC Acquires New Stake in Benitec Biopharma Inc (GuruFocus.com)
Aug-18-23 09:02PM	JANUS HENDERSON GROUP PLC Acquires New Stake in Benitec Biopharma Inc (GuruFocus.com)
Aug-11-23 01:00PM	Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering (GlobeNewswire)
Aug-08-23 10:30PM	Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering (GlobeNewswire) +65.80%
Jul-25-23 01:00PM	Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023 (GlobeNewswire)
Jun-26-23 08:00AM	Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (GlobeNewswire) +80.90%
May-15-23 08:00AM	Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire)
May-08-23 08:05AM	Benitec Biopharma to Present at the OPMD International Conference (GlobeNewswire)
08:00AM	Benitec Biopharma to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
Feb-13-23 08:00AM	Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire)
Jan-23-23 09:48AM	Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program (GlobeNewswire) +9.08%
Nov-10-22 08:00AM	Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire) +5.79%
Sep-16-22 08:42AM	Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering (GlobeNewswire) -15.43%
Sep-12-22 10:06PM	Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering (GlobeNewswire) -6.63% -28.34%
Sep-02-22 08:00AM	Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update (GlobeNewswire)
Jul-15-22 06:52AM	Having purchased US$827k worth of Benitec Biopharma Inc. (NASDAQ:BNTC) stock, the recent 11% pullback is not what insiders may have expected (Simply Wall St.) +7.00%
May-16-22 08:15AM	Benitec Biopharma Releases Q3 2022 Financial Results (GlobeNewswire) -8.79%
Feb-14-22 08:00AM	Benitec Biopharma Discloses Q2 2022 Financial Results (PR Newswire)
Jan-18-22 12:53PM	/C O R R E C T I O N from Source -- Norra Metals Corp./ (PR Newswire) -6.64%
Jan-17-22 09:30AM	Norra Metals Announces Private Placement Financing (PR Newswire)
Nov-27-21 06:54AM	We're Keeping An Eye On Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate (Simply Wall St.)
Nov-15-21 08:00AM	Benitec Biopharma Discloses Q1 2022 Financial Results (PR Newswire)
Sep-20-21 08:00AM	Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results (PR Newswire) -7.86%
Sep-13-21 03:58PM	Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference (PR Newswire)
Sep-08-21 08:10AM	Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022 (PR Newswire)
08:05AM	Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals (PR Newswire)

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 29 '25	Buy	13.44	77,387	1,040,081	9,700,195	Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 23 '25	Buy	12.85	50,000	642,500	9,620,075	Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 26 '25	Buy	13.10	16,836	220,552	9,634,395	Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 22 '25	Buy	12.08	19,542	236,067	9,577,475	Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 19 '25	Buy	11.48	16,384	188,088	9,560,825	Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 18 '25	Buy	11.24	10,215	114,817	9,546,875	Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Nov 07 '25	Buy	13.50	1,481,481	19,999,994	9,538,175	Nov 10 09:51 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Mar 31 '25	Buy	12.83	16,497	211,736	8,807,805	Apr 02 04:37 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Mar 26 '25	Buy	13.00	900,000	11,700,000	8,793,245	Mar 28 04:51 PM
BUCHI J KEVIN	Director	Feb 27 '25	Option Exercise	3.86	51,813	199,998	103,910	Mar 03 02:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BNTC

Benitec Biopharma Inc

Upgrade your FINVIZ experience